Results 1 to 10 of about 71,560 (137)
Glucagon-like peptide-1-(7-36) amide (GLP-1) is a human incretin hormone responsible for the release of insulin in response to food. Pre-clinical and human physiological studies have demonstrated cardioprotection from ischemia-reperfusion injury.
Joel P. Giblett, BM, BSc +3 more
doaj +3 more sources
Glucagon-like peptide 1 (GLP-1) [PDF]
Background: The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying ...
T.D. Müller +24 more
doaj +8 more sources
Potential role of glucagon like peptide 1 in taste receptors [PDF]
The perception of taste is a complex physiological process that extends far beyond the simple detection of flavor molecules, serving as a critical interface between nutrient sensing, metabolic regulation, and feeding behavior.
Jose Luis Eduardo Doval-Caballero +11 more
doaj +2 more sources
Glucagon-like peptide-1 receptor agonists in orthopaedics [PDF]
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RA) help people control blood glucose and lose weight. They may also help with bone metabolism, healing fractures, keeping joints healthy, and recovering after surgery.
Mavrogenis Andreas F. +7 more
doaj +2 more sources
Equine glucagon-like peptide-1 receptor physiology [PDF]
Background Equine metabolic syndrome (EMS) is associated with insulin dysregulation, which often manifests as post-prandial hyperinsulinemia. Circulating concentrations of the incretin hormone, glucagon-like peptide-1 (GLP-1) correlate with an increased ...
Murad H. Kheder +4 more
doaj +5 more sources
Glucagon-like peptide-1 analogues: An overview
Abnormalities of the incretin axis have been implicated in the pathogenesis of type 2 diabetes mellitus. Glucagon-like peptide-1 (GLP-1) and gastroinhibitory intestinal peptide constitutes >90% of all the incretin function.
Vishal Gupta
doaj +3 more sources
Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Arrhythmias [PDF]
Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), initially designed to treat diabetes mellitus (DM), have demonstrated the potential to mitigate obesity‐related cardiovascular risks.
Vikash Jaiswal +12 more
doaj +2 more sources
Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
Accumulating evidence suggests that metabolic demands of the regenerating liver are met via lipid metabolism and critical regulators of this process. As such, glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) critically affect hepatic ...
Markus Ammann +9 more
doaj +1 more source
Aims/Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are used for treatment of type 2 diabetes mellitus worldwide. However, some patients do not respond well to the therapy, and caution must be taken for certain patients, including those
Takaaki Murakami +5 more
doaj +1 more source
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes [PDF]
The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from various diabetes-related complications. Since there are many patients with T2D that cannot be controlled by previously developed drugs, it has been necessary ...
Seungah Lee, Dong Yun Lee
doaj +1 more source

